Enterprise Investors exits Nu-Med Grupa
Warsaw, 20 August 2024 — Polish Enterprise Fund VII, a private equity fund managed by Enterprise Investors (El), announces the sale of Nu-Med, a leading Polish company specializing in radiotherapy treatment for cancer patients. The buyer, Affidea, is a pan-European provider of specialist healthcare services, including cancer care, advanced diagnostic imaging and community-based polyclinics. The deal is subject to approval by the Polish Office of Competition and Consumer Protection.
Nu-Med’s journey with EI began in 2013 when PEF VII acquired a significant minority stake in the company, which then operated a single radiotherapy center in Elbląg, northern Poland. In the previous year EI made its first investment in radiotherapy in Katowice, southern Poland. The two radiotherapy centers subsequently merged under the Nu-Med banner and two more treatment centers were opened: one in Tomaszów Mazowiecki, located in the center of the country, and the other in Zamość, situated in eastern Poland.
Over the past decade, Nu-Med has maintained its commitment to high-quality treatment and patient care. The company’s strong position among healthcare providers is reflected in its solid financial standing, with 2023 revenues reported at the level of more than EUR 60 million.
Michał Rusiecki, EI’s managing partner responsible for the investment, said: “This exit represents a significant milestone both in Nu-Med’s growth and in EI’s investment strategy in the healthcare sector, underscoring the firm’s commitment to creating value in this critical sector. We are extremely proud that during our investment period we provided critical care to almost 70,000 patients.” He added: “From a single radiotherapy center, we’ve grown Nu-Med into a leading provider of cancer care. The sale to Affidea ensures that Nu-Med will continue providing high-quality, comprehensive cancer care to patients across Poland as part of a premier international organization.”
Mesut Göral, CEO of Affidea Poland, Senior Vice President and COO for Affidea Group, commented on the acquisition: “Cancer remains a leading threat in our communities, being the second most common cause of death in Poland with around 170,000 new cases and 100,000 deaths annually, according to WHO. This acquisition highlights Affidea’s commitment to supporting the National Oncology Strategy, ensuring better access to top-quality services for cancer prevention, early diagnosis, and treatment, in a comprehensive and integrated manner. Nu-Med’s renowned radiotherapy centre, led by their Senior Leadership Team and highly qualified clinical and non-clinical colleagues, perfectly complements Affidea’s operations and culture. We look forward to working together, after the closing, in our common mission of fighting against cancer.”
Enterprise Investors is one of the largest private equity firms in Central and Eastern Europe. Active since 1990, the firm has raised ten funds, which have invested and committed EUR 2.3 billion in 156 companies and exited 140 companies.
Affidea Group is the pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider, including cancer care. Founded in 1991, the company operates 366 centres across 15 countries, providing high-quality medical services to nearly 14 million patients every year. Affidea is majority-owned by Groupe Bruxelles Lambert (GBL), a leading investment holding company, focused on long-term value-creation with a stable and supportive family shareholder base.
For further information please contact:
Anna Czywczyńska, Communications & Public Affairs Director tel.: +48 22 458 8500